drugset / Trial / NCT03561298
A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to evaluate the safety and pharmacokinetic interaction of effects of multiple doses of zanubrutinib with a "Cocktail" of five probe drugs for cytochrome P450 (CYP) 3A, CYP2C9, CYP2C19, P-glycoprotein and breast cancer resistance protein (BCRP) in healthy subjects
Timeline
- Start
- 2018-06-07
- Primary completion
- 2018-06-07
- Completion
- 2018-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Digoxin | Other / unclassified | — | — |
| Subject | Midazolam | Small molecule | — | — |
| Subject | Omeprazole | Other / unclassified | — | — |
| Subject | Rosuvastatin | Small molecule | — | — |
| Subject | Warfarin | Small molecule | — | — |
| Subject | Zanubrutinib | Small molecule | — | — |
Indications
No indication recorded.